Subscribe to Newsletter
Manufacture Advanced Medicine

Allogenic Advance

Two-out-of-four patients in a 300 million-cell cohort, and one-out-of-three in a 100-cell cohort, achieved a complete response following treatment with CRISPR Therapeutics’ allogeneic CAR T cell therapy CTX110 (1). 

The B-cell malignancy treatment was safe at the 300-million dose level and below. The only patient who received a 600 million-cell dose, after initially achieving a complete response, was hospitalized with febrile neutropenia and later died after reactivation of HHV-6 and HHV-6 encephalitis.

CTX110 is derived from healthy donor T cells, which are modified using CRISPR/Cas 9 to i) insert a CAR construct, which binds to cancer cells and activates T cells and ii) knock out the T cell receptor and MHC1, which reduces the risk of graft versus host disease and rejection.

Receive content, products, events as well as relevant industry updates from The Medicine Maker and its sponsors.
Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

  1. CRISPR Therapeutics (2020). Available at:
About the Author
James Strachan

Over the course of my Biomedical Sciences degree it dawned on me that my goal of becoming a scientist didn’t quite mesh with my lack of affinity for lab work. Thinking on my decision to pursue biology rather than English at age 15 – despite an aptitude for the latter – I realized that science writing was a way to combine what I loved with what I was good at.


From there I set out to gather as much freelancing experience as I could, spending 2 years developing scientific content for International Innovation, before completing an MSc in Science Communication. After gaining invaluable experience in supporting the communications efforts of CERN and IN-PART, I joined Texere – where I am focused on producing consistently engaging, cutting-edge and innovative content for our specialist audiences around the world.

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine